Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PEPD | P12955 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23513602 | 1.00 | PEPD (0.36) | PEPDGRM2GRM3MAPTCYP2C19 | |
| SCHEMBL23513641 | 0.85 | MAPT (0.33) | PEPDMAPTCYP2C19 | |
| SCHEMBL26724098 | 0.85 | PEPD (0.36) | PEPD | |
| SCHEMBL23513648 | 0.83 | ACE (0.32) | PEPDMAPTPOLBTSHR | |
| SCHEMBL24710045 | 0.83 | PEPD (0.35) | PEPD | |
| SCHEMBL19115343 | 0.82 | GRIK1 (0.35) | GRM2GRM3MAPTAPLNR | |
| SCHEMBL18027861 | 0.82 | GRIK1 (0.35) | GRM2GRM3MAPTAPLNR | |
| SCHEMBL26206857 | 0.80 | PEPD (0.51) | PEPDPOLB | |
| SCHEMBL24962696 | 0.80 | PEPD (0.36) | PEPD | |
| SCHEMBL24709992 | 0.78 | PEPD (0.32) | PEPD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612156-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20240199647-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-20 | — | — | US | disclosed |
| WO-2024097296-A1 | ANTI-VIRAL COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2022166923-A1 | PHENYLDIHYDROPYRIMIDINE COMPOUND AND USE THEREOF | 和博医药有限公司 | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199647-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | PEPD 651/4885GRM2 4679/4885GRM3 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.